One of the most difficult questions in oncology is: “How long do I have to live?”

Patients often bring this up to their physicians following a diagnosis of cancer, and periodically during the course of their disease.

Of course, this is an impossible question to answer because we as physicians can seldom predict what the future holds for a particular patient. We can prob­a­bly estimate averages, but no patient is average; everyone is unique. Faced with this dilemma, each physician responds differently. Some provide the averages, some don’t.

Nevertheless, it is incredibly …

Myeloma specialists from the Czech Republic have published clinical trial results that shed further light on chromosomal abnormalities and their impact on survival in newly diag­nosed multiple myeloma patients.

Specifically, the researchers found that patients with three or more chromos­omal abnor­malities, a gain in the 1q21 region, or the trans­location t(4;14) have reduced survival compared to patients without such abnormalities.

According to the researchers, their findings highlight the importance of chromosomal abnormalities when considering treatment options for myeloma patients.

They note, however, that their findings need to be confirmed in a pro­spective, …

Since I got my myeloma diagnosis five and a half years ago, I haven’t been given to bouts of depression.

With a myeloma diagnosis, you really don’t have time to feel sorry for yourself.

I’ve tried to take in stride all the things “they” have done to me – two autologus stem cell transplants, a myriad of chemotherapy side effects, an open lung biopsy, and endless needle sticks, just to name a few.

Then there’s the prodding, probing, and testing by various doctors and specialist of all kinds.  There were spur-of-the-moment ultrasounds …

According to a recent Italian study, the results of PET/CT scans conducted at diagnosis, after induction therapy, and after stem cell transplantation may predict survival in multiple myeloma patients.

Specifically, the study authors found that patients with PET/CT scans negative for cancer cells, bone lesions, or other signs of active cancer had longer progression-free and overall survival times than patients with positive PET/CT scans.

“[Our study shows] a clear identification of the prognostic relevance of PET/CT [along with] other more known prognostic factors such as chromosomal abnormalities,” said Dr. Elena Zamagni of …

A recent European study reported poorer overall survival in patients with rare IgD, IgE, and IgM multiple myelomas following stem cell transplantation compared to patients with the more common IgG, IgA, or light chain myelomas. However, the overall survival of nonsecretory myeloma patients, another rare type of myeloma, was similar to that of common myeloma patients.

The authors added that the survival data from their analysis is better than previous data for patients with rare myelomas who received a stem cell transplant. They therefore recommended the continued use of transplantation as a …

Early-stage myeloma, single bone lesions, a negative bone marrow biopsy, and normal M-protein levels in the serum are associated with improved survival in multiple myeloma patients following surgery for skeletal complications, according to a recent German study.

Multiple myeloma is commonly associated with a number of skeletal complications, including fractures, spinal cord compression, elevated calcium levels in the blood, and severe bone pain.

These complications arise as a result of skeletal weakening due to bone lesions. Bone lesions are the result of an under activity or absence of cells responsible for bone …

A recent study reported that long-term surviving myeloma patients are generally younger and have received and responded well to treatment with conventional chemotherapy. Dr. M. Kraj of the Institute of Hematology and Transfusion Medicine in Warsaw, Poland, presented the findings at the European Hematology Association (EHA) meeting in Barcelona last month.

Dr. Kraj and her colleagues aimed to identify common clinical and laboratory features in long-term surviving myeloma patients, as these may assist physicians in determining an accurate prognosis for other patients.

The researchers analyzed data of 600 myeloma patients diagnosed before …